PMID- 28681154 OWN - NLM STAT- MEDLINE DCOM- 20180730 LR - 20210728 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 24 IP - 11 DP - 2017 Oct TI - Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. PG - 3212-3219 LID - 10.1245/s10434-017-5988-y [doi] AB - BACKGROUND: Prediagnosis obesity and diabetes are associated with survival from pancreatic cancer, but the underlying mechanisms have not been characterized. Because both are associated with dysregulation in circulating insulin-like growth factor (IGF) levels, we evaluated the associations of prediagnosis IGF levels (IGF-I, IGF-II) and IGF binding protein 3 (IGFBP-3) with pancreatic cancer survival. METHODS: Participants were subjects enrolled in the intervention arm of the PLCO Cancer Screening Trial who developed exocrine pancreatic cancer during follow-up (N = 178, 116 men and 67 women). Participants provided blood samples at enrollment, before cancer diagnosis. Cox proportional hazards regression model, adjusted for confounders was used to investigate associations of IGF biomarkers with pancreatic cancer survival. Because of the well-documented, gender-specific differences in circulating IGF biomarkers, and differential associations of IGF biomarkers with mortality, we evaluated associations separately among males and females. RESULTS: Median survival was 172 days. Higher IGF-II and IGFBP-3 levels were associated with pancreatic cancer survival among males but not among females. The hazard ratios (HR) of death among men in the highest tertiles of IGF-II and IGFBP-3 compared with men in the lowest tertiles were 0.40 (95% confidence interval (CI) 0.23-0.71, p < 0.01) and 0.59 (95% CI 0.35-0.97, p = 0.10), respectively. There were no statistically significant associations between IGF-I concentrations, IGF-I/IGFBP-3, and pancreatic cancer survival. CONCLUSIONS: Higher prediagnosis circulating IGF-II and IGFBP-3 levels are associated with better pancreatic cancer survival among men but not women. A greater understanding of how IGF signaling is related to pancreatic cancer survival could have utility in improving pancreatic cancer prognosis. FAU - Toriola, Adetunji T AU - Toriola AT AD - Department of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. a.toriola@wustl.edu. FAU - Ziegler, Mark AU - Ziegler M AD - Department of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. FAU - Li, Yize AU - Li Y AD - Department of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. FAU - Pollak, Michael AU - Pollak M AD - Department of Oncology, McGill University, Montreal, Canada. FAU - Stolzenberg-Solomon, Rachael AU - Stolzenberg-Solomon R AD - Branch of Nutritional Epidemiology, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. LA - eng GR - ZIA CP010202/ImNIH/Intramural NIH HHS/United States PT - Journal Article DEP - 20170705 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (Biomarkers, Tumor) RN - 0 (IGF1 protein, human) RN - 0 (IGF2 protein, human) RN - 0 (IGFBP3 protein, human) RN - 0 (Insulin-Like Growth Factor Binding Protein 3) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 67763-97-7 (Insulin-Like Growth Factor II) SB - IM MH - Aged MH - Biomarkers, Tumor/*blood MH - Female MH - Follow-Up Studies MH - Humans MH - Insulin-Like Growth Factor Binding Protein 3/*blood MH - Insulin-Like Growth Factor I/*analysis MH - Insulin-Like Growth Factor II/*analysis MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Pancreatic Neoplasms/blood/*mortality/pathology MH - Prognosis MH - Survival Rate PMC - PMC8313435 MID - NIHMS1720689 COIS- Disclosure The authors declare no potential conflicts of interest. EDAT- 2017/07/07 06:00 MHDA- 2018/07/31 06:00 PMCR- 2021/07/27 CRDT- 2017/07/07 06:00 PHST- 2017/04/03 00:00 [received] PHST- 2017/07/07 06:00 [pubmed] PHST- 2018/07/31 06:00 [medline] PHST- 2017/07/07 06:00 [entrez] PHST- 2021/07/27 00:00 [pmc-release] AID - 10.1245/s10434-017-5988-y [pii] AID - 10.1245/s10434-017-5988-y [doi] PST - ppublish SO - Ann Surg Oncol. 2017 Oct;24(11):3212-3219. doi: 10.1245/s10434-017-5988-y. Epub 2017 Jul 5.